Waverly Advisors LLC Has $81.17 Million Stake in AbbVie Inc. $ABBV

Key Points

• Waverly Advisors increased its AbbVie stake by 43.6% in the second quarter, adding 97,882 shares to hold 322,558 shares worth approximately $81.17 million. Institutional investors collectively own 70.23% of ABBV.
• AbbVie beat quarterly expectations with EPS of $3.65 and revenue of $16.99 billion, up 10.2% year over year. Analysts maintain a “Moderate Buy” consensus with an average price target of $276.64.
• The company declared a quarterly dividend of $1.73 per share, equivalent to a $6.92 annualized payout and a 2.7% yield. An executive also sold 32,710 shares for about $8.18 million, reducing his ownership by 30.53%.

Waverly Advisors LLC increased its stake in AbbVie Inc. (NYSE:ABBV - Free Report) by 43.6% in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 322,558 shares of the company's stock after acquiring an additional 97,882 shares during the quarter. Waverly Advisors LLC's holdings in AbbVie were worth $81,168,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter valued at $28,000. Imprint Wealth LLC boosted its position in shares of AbbVie by 56.2% during the 4th quarter. Imprint Wealth LLC now owns 125 shares of the company's stock worth $29,000 after purchasing an additional 45 shares in the last quarter. Burk Holdings LLC bought a new position in shares of AbbVie during the 2nd quarter worth about $30,000. IFC & Insurance Marketing Inc. acquired a new stake in shares of AbbVie in the 4th quarter valued at about $31,000. Finally, Abound Financial LLC acquired a new stake in shares of AbbVie in the 4th quarter valued at about $32,000. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Activity

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company's stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Price Performance

ABBV opened at $257.17 on Monday. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $267.47. The firm has a market capitalization of $454.36 billion, a PE ratio of 72.65, a P/E/G ratio of 1.16 and a beta of 0.29. The company's 50-day moving average is $254.46 and its 200 day moving average is $230.95.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company's quarterly revenue was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, analysts expect that AbbVie Inc. will post 14.05 EPS for the current year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.7%. AbbVie's payout ratio is presently 195.48%.

Analyst Upgrades and Downgrades

ABBV has been the topic of a number of research reports. JPMorgan Chase & Co. upped their price target on AbbVie from $260.00 to $280.00 and gave the stock an "overweight" rating in a research note on Thursday, July 9th. Weiss Ratings raised AbbVie from a "hold (c)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. Erste Group Bank upgraded AbbVie from a "hold" rating to a "buy" rating in a report on Wednesday, August 5th. Sanford C. Bernstein reaffirmed a "market perform" rating on shares of AbbVie in a research report on Tuesday, June 23rd. Finally, Citigroup increased their target price on AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and five have issued a Hold rating to the company's stock. According to MarketBeat.com, AbbVie currently has an average rating of "Moderate Buy" and an average target price of $276.64.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Positive Phase 3 menstrual-migraine results: Atogepant met the primary and secondary endpoints in the LUNA late-stage study, demonstrating reductions in menstrual migraine days along with positive safety and efficacy results. The data could support regulatory expansion of Qulipta into an indication with no specifically approved targeted therapies, potentially broadening AbbVie’s migraine franchise. AbbVie's Atogepant Meets Goal in Late-Stage Menstrual Migraine Study
• Positive Sentiment: Potentially more flexible treatment use: The results support intermittent preventive treatment around menstruation, which could expand Qulipta’s addressable market beyond continuous daily migraine prevention. Investors view the outcome as evidence of continued momentum in AbbVie’s migraine business. AbbVie Gains as Qulipta Opens a New Migraine Market
• Positive Sentiment: Additional pipeline catalyst: AbbVie completed its ECLIPSE migraine trial, setting up another potential data milestone for the company’s migraine portfolio. A favorable outcome could further strengthen its competitive position in the CGRP market.
• Neutral Sentiment: Dividend maintained: AbbVie declared a quarterly dividend of $1.73 per share, payable November 16 to shareholders of record October 15. The declaration reinforces the income appeal of ABBV but does not represent a new increase in the payout.
• Neutral Sentiment: Analyst confidence remains favorable: HSBC raised its price target to $315 from $300 while maintaining a Buy rating, reflecting optimism about AbbVie’s newer growth products and pipeline.
• Negative Sentiment: Ongoing concentration concerns: Investors continue to monitor AbbVie’s reliance on Skyrizi and Rinvoq to offset Humira’s patent-related decline. The stock’s elevated valuation also leaves less room for disappointment if pipeline launches or immunology growth slow.

AbbVie Company Profile

AbbVie Inc NYSE: ABBV is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott's diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie's immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.